The 64 references in paper A. Vyalkova A., E. Lebedeva N., S. Krasikov I., I. Zorin V., E. Kulagina P., S. Nikolaeva N., А. Вялкова А., Е. Лебедева Н., С. Красиков И., И. Зорин В., Е. Кулагина П., С. Николаева Н. (2014) “Клинико-патогенетические аспекты повреждения почек при ожирении (обзор литературы) // Clinical and paphogenical aspects of kidney damage in obesity (review)” / spz:neicon:nefr:y:2014:i:3:p:24-33

1
Бутрова СА, Дзгоева ФХ. Висцеральное ожирение – ключевое звено метаболического синдрома. Ожирение и метаболизм 2004; (1): 10–16 [Butrova SA, Dzgoeva FH. Visceral'noe ozhirenie – kljuchevoe zveno metabolicheskogo sindroma. Ozhirenie i metabolizm 2004; (1): 10–16]
(check this in PDF content)
2
Вялкова АА, Николаева СН, Лебедева ЕН и др. Характеристика липидного обмена при ожирении у детей с нефропатиями. Материалы III научно-практическая конференция «Педиатрия и детская хирургия в Приволжском федеральном округе». Казань, 2006;107-108 [Vjalkova AA, Nikolaeva SN, Lebedeva EN i dr. Harakteristika lipidnogo obmena pri ozhirenii u detej s nefropatijami. Materialy III nauchno-prakticheskaja konferencija «Pediatrija i detskaja hirurgija v Privolzhskom federal’nom okruge». Kazan’, 2006; 107-108]
(check this in PDF content)
3
Гинзбург ММ, Козупица ГС. Значение распределения жира при ожирении Пробл эндокр 1996; 42(3): 42–46 [Ginzburg MM, Kozupica GS. Znachenie raspredelenija zhira pri ozhirenii Probl jendokr 1996; 42(3): 42–46]
(check this in PDF content)
4
Дедов ИИ, Мельниченко ГА, Романцова ТИ. Патогенетические аспекты ожирения. Ожирение и метаболизм 2004; (1): 3–9 [Dedov II, Mel’nichenko GA, Romancova TI. Patogeneticheskie aspekty ozhirenija. Ozhirenie i metabolizm 2004; (1): 3–9]
(check this in PDF content)
5
Кутырина И., Краснова Е., Федорова Е., Фомин В. Поражение почек при ожирении: клинические, патогенетические и терапевтические аспекты. Врач 2005; (6):6-9 [Kutyrina I., Krasnova E., Fedorova E., Fomin V. Porazhenie pochek pri ozhirenii: klinicheskie, patogeneticheskie i terapevticheskie aspekty. Vrach 2005; (6):6-9]
(check this in PDF content)
6
Ogden CL , Yanovski SZ, Carroll MD, Flegal KM The epidemiology of obesity. Gastroenterology 2007; 132: 2087-2102
(check this in PDF content)
7
Мухин НА, Балкаров ИМ, Моисеев СВ и др. Хронические прогрессирующие нефропатии и образ жизни современного человека Тер арх 2004; (9): 5-11 [Muhin NA, Balkarov IM, Moiseev SV i dr. Hronicheskie progressirujushhie nefropatii i obraz zhizni sovremennogo cheloveka Ter arh 2004; (9): 5-11]
(check this in PDF content)
8
Мухин НА, Шоничев ДГ, Балкаров ИМ и др. Формирование артериальной гипертонии при уратном тубулоинтерстициальном поражении почек Тер. арх 1999; (6): 12-24 [Muhin NA, Shonichev DG, Balkarov IM i dr. Formirovanie arterial‘noj gipertonii pri uratnom tubulointersticial‘nom porazhenii pochek Ter. arh 1999; (6): 12-24]
(check this in PDF content)
9
Kambham N, Markowitz G, Valeri A et al. Obesity-related glomerulopathy: An emerging epidemic. Kidney Int 2001;59: 1498-1509
(check this in PDF content)
10
Николаева СН, Лебедева ЕН, Вялкова АА и др. Клиническая оценка уровня лептина и инсулина в крови у детей с ожирением. Совр вопросы педиатрии 2007; (5):485-486 [Nikolaeva SN, Lebedeva EN, Vyalkova AA i dr. Klinicheskaja ocenka urovnja leptina i insulina v krovi u detej s ozhireniem. Sovr voprosy pediatrii 2007; (5):485-486]
(check this in PDF content)
11
Мухин НА, Арутюнов ГП, Фомин ВВ. Альбуминурия – маркер поражения почек и риска сердечно-сосудистых осложнений Клин нефр 2009;(1): 5-10 [ Muhin NA, Arutjunov GP, Fomin VV. Al’buminurija – marker porazhenija pochek i riska serdechno-sosudistyh oslozhnenij Klin nefr 2009;(1): 5-10]
(check this in PDF content)
12
Сигитова ОН, Бикмухамметова ЭИ, Надеева РА. Микроальбуминемия – диагностическое и прогностическое значение при артериальной гипертонии. Арт гипертенз 2009;15(6):627-632 [Sigitova ON, Bikmuhammetova JeI, Nadeeva RA. Mikroal’buminemija – diagnosticheskoe i prognosticheskoe znachenie pri arterial’noj gipertonii. Art gipertenz 2009;15(6):627632]
(check this in PDF content)
13
Papafragkaki DK, Tolis G. Obesity and renal disease: A possible role of leptin. Hormones 2005; 4(2):90-95
(check this in PDF content)
14
Сагинова ЕА, Фомин ВВ, Моисеев СВ, Лебедева МВ. Поражения почек при ожирении. Тер арх 2007;(5):88-94 [Saginova EA, Fomin VV, Moiseev SV, Lebedeva MV. Porazhenija pochek pri ozhirenii. Ter arh 2007;(5):88-94 ]
(check this in PDF content)
15
Федорова ЕЮ, Кутырина ИМ. Механизмы прогрессирования поражения почек при ожирении. Нефрология и диализ 2006;(2):3-12 [Fedorova EJu, Kutyrina IM. Mehanizmy progressirovanija porazhenija pochek pri ozhirenii. Nefrologija i dializ 2006;(2):3-12]
(check this in PDF content)
16
Wickman C, Kramer H. Obesity and kidney disease: potential mechanisms. Semin Nephrol. 2013 Jan; 33(1):14-22.
(check this in PDF content)
17
Praga M, Hernаndez E, Morales E. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant2001;15: 1790-1798
(check this in PDF content)
18
Meier-Krieshce HU, Vaghela M, Thambuganipalle R. The effect of body index on long-trem renal allograft survival.Transplantation1999;68: 1294-1297
(check this in PDF content)
19
Ahima RS. Linking adiponectin to proteinuria. JCI 2008; 118(2): 1619-1622
(check this in PDF content)
20
Coresh J. Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298:2038-2047
(check this in PDF content)
21
Kramer H. Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. Am. J. Kidney Dis. 2005; (46):587-594
(check this in PDF content)
22
Villarreal D, Reams G, Freeman RH, Taraben A. Renal effects of leptin in normotensive, hypertensive and obese rats. Am J Physiol 1998; 275: 2056-2060
(check this in PDF content)
23
Kohan DE. Endothelins in the normal and diseased kidney. Am. J Kidney Dis 1996; 1: 2-26
(check this in PDF content)
24
Adamczak M, Wiecek A. The adipose tissue as an endocrine organ. Semin Nephrol. 2013 Jan; 33(1):2-13.
(check this in PDF content)
25
Saxena AK , Chopra R. Renal risk of an emerging epidemic of obesity: the role of adipocyte-derived factors. Nephrol Dial Transplant 2004; 33: 11-20
(check this in PDF content)
26
Stijn CM, Kim J, Barish GD. Adiponectin expression protects against angiotensin II-mediated inflammation and accelerated atherosclerosis. PLoS One. 2014 Jan 22; 9 (1):e86404.
(check this in PDF content)
27
Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis 2002;39: 1-11
(check this in PDF content)
28
Wolf G. Obesity and Renal Disease: Introduction. Semin Nephrol. 2013 Jan; 33(1):1.
(check this in PDF content)
29
Han DC, Isono M, Chen S. Leptin stimulates type I collagen production in db/db mesangial cells: glucose uptake and TGF-beta type II receptor expression. Kidney Int 2001; 59:1315-1323
(check this in PDF content)
30
Hong SW, Isono M, Chen S et al. Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/ db mouse.Am J Pathol 2001;158: 1653-1663
(check this in PDF content)
31
Allessi MC, Peiretti F, Morange P. et al. Production of plasminogen activator inghibitor-1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes1997; 46: 860-867
(check this in PDF content)
32
Engeli S, Negel R, Sharma AM. Pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000; 35: 1270- 1276
(check this in PDF content)
33
Rüster C, Wolf G. The role of the renin-angiotensinaldosterone system in obesity-related renal diseases. Semin Nephrol. 2013 Jan; 33(1):44-53
(check this in PDF content)
34
Baud L, Fouqueray B, Amrani PC. Tumor necrosis factor alpha and mesangial cells Kidney Int 1992; 41: 600-603
(check this in PDF content)
35
Stenvinkel P. Leptin and its clinical implications in chronic renal failure Miner Electrolyte Metab 1999;25: 298-302
(check this in PDF content)
36
Locatelli F, Pozzoni P, Del Vecchio L. Renal manifestations in the metabolic syndrome.J. Am. Soc. Nephrol. 2006;17(4, 2):S81-S85
(check this in PDF content)
37
Sharma K, Considini RV, Beckie M. et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Intern 1997; 51:1980-1985
(check this in PDF content)
38
Nasrallah MP, Ziyadeh FN. Overview of the physiology and pathophysiology of leptin with special emphasis on its role in the kidney. Semin Nephrol. 2013 Jan; 33(1):54-65.
(check this in PDF content)
39
Pistrosch F. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005; 54:2206-2211
(check this in PDF content)
40
Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo RA. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int 2007;72:1367-1373
(check this in PDF content)
41
Pajvani UB Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J. Biol. Chem. 2004;279:12152-12162
(check this in PDF content)
42
Bonnet F, Deprele C, Sassolas A. et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA-nephritis .Am J Kidney Dis 2001; 37: 720-727
(check this in PDF content)
43
Siddiqi FS, Advani A. Endothelial-Podocyte Crosstalk: The Missing Link Between Endothelial Dysfunction and Albuminuria in Diabetes. Diabetes 2013;.62 (11): 3647-3655
(check this in PDF content)
44
Lee MJ. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 2007;292:F617-F627
(check this in PDF content)
45
Henegar J, Bigler S, Henegar L. et al. Functional and structural changes in the kidney in the early stages of obesity. Am J Soc Nephrol 2001;12: 1211-1217
(check this in PDF content)
46
Sharma K, McCue P, Dunn S. Diabetic kidney disease in the db/db mouse. Am J Renal Physiol 2003; 284: 1138-1144
(check this in PDF content)
47
Verani RR, Grоne EF. The role of lipids in nephrosclerosis and glomerulosclerosis Atherosclerosis 1994; 107: 1-13
(check this in PDF content)
48
Sharma K. Adiponectin regulates albuminuria and podocyte function in mice. J. Clin. Invest. 2008; 118:1645-1656
(check this in PDF content)
49
Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int 2009;76:145-148
(check this in PDF content)
50
Kadowaki T. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 2006;116:1784-1792
(check this in PDF content)
51
Nawrocki AR. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J. Biol. Chem. 2006; 281:2654-2660
(check this in PDF content)
52
Yamauchi T, Nio Y, Maki T. et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat. Med.2007;13:332-339
(check this in PDF content)
53
Ohashi K. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler Thromb Vasc Biol 2007; 27:1910-1917
(check this in PDF content)
54
Ouedraogo R, Gong Y, Bercins B. et al. Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest 2007;117:1718-1726
(check this in PDF content)
55
Yano Y. Differential impacts of adiponectin on low-grade albuminuria between obese and nonobese persons without diabetes .J Clin Hypertens (Greenwich) 2007; 9:775-782
(check this in PDF content)
56
Looker HC. Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab 2004; 89:4010-4017
(check this in PDF content)
57
Dengel DR, Glodberg AP, Mayuga RS. et al. Insulin resistance, elevated glomerular filtration fraction and renal injury. Hypertension 1996; 28:127-132
(check this in PDF content)
58
Наточин ЮВ. Нефрология и фундаментальная наука. Нефрология 2012; 16: 9-21 [NatochinYuV. Nephrologija i fundamental’naja nauka. Nephrologija 2012; 16: 9-21]
(check this in PDF content)
59
Смирнов АВ, Шилов ЕМ, Добронравов ВА. Национальные Рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Нефрология 2012; 16: 89-115 [Smirnov AV, Shilov EM, Dobronravov VA. National’nye Recommendacii. Chronicheskaja bolezn’ pochek: osnovnye principy screninga, diagnostiki, profilaktiki i podhody k lecheniju. Nephrologija 2012; 16: 89-115]
(check this in PDF content)
60
Wiecek A, Kokot F, Chudek J , Adamczak M. The adipose tissue – a novel endocrine organ of interest to the nephrologists. Nephrol Dial Transplant 2002; 17: 191–195
(check this in PDF content)
61
Risheng Y, Scherer PE. Adiponectin, driver or passenger on the road to insulin sensitivity? Mol Metab 2013; 2(3): 133–141
(check this in PDF content)
62
Stenvinkel P.Adiponectin in chronic kidney disease: a complex and context sensitive clinical situation. Journal of Renal Nutrition.2011; 21(1):82-86
(check this in PDF content)
63
Park SH, Carrero JJ, Lindholm B, Stenvinkel P. Adiponectin in chronic kidney disease has an opposite impact on protein-energy wasting and cardiovascular risk: two sides of the same coin. Clin Nephrol. 2009 Aug; 72(2):87-96.
(check this in PDF content)
64
Jeon WS, Park JW, Lee N et al. Urinary adiponectin concentration is positively associated with micro- and macrovascular complications. Cardiovasc Diabet 2013; 12:137 Авторы заявляют об отсутствии конфликта интересов.
(check this in PDF content)